Form 4: Corcept Therapeutics Officer Reports Stock Transactions

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock acquisitions, disposals, and option grants.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Robb disposed of 250 shares to cover tax obligations at a price of $60.58 per share.
• On the same day, he acquired 292 shares at $59.07 per share and another 292 shares at $0 per share under a purchase plan.
• Following these transactions, Robb directly owns 23,490 shares of common stock.
• He also indirectly owns 9,665 shares through a custodial account for his child.
• On February 28, 2025, Robb was granted options to purchase 140,000 shares at an exercise price of $60.58, vesting monthly over four years.
• The options expire on February 28, 2035.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, reflecting routine transactions. The sentiment is neutral as it simply reports facts without expressing any opinion or prediction.

Positives

• The acquisition of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the trading activity of a key company officer.

Key Dates